Mostrar el registro sencillo del ítem
Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/ French-Language Oncology Group (GOLF)
dc.rights.license | open | en_US |
dc.contributor.author | GREILLIER, Laurent | |
dc.contributor.author | GAUVRIT, Manon | |
dc.contributor.author | PAILLAUD, Elena | |
dc.contributor.author | GIRARD, Nicolas | |
dc.contributor.author | MONTEGUT, Coline | |
dc.contributor.author | BOULAHSSASS, Rabia | |
dc.contributor.author | WISLEZ, Marie | |
dc.contributor.author | PAMOUKDJIAN, Frederic | |
dc.contributor.author | CORRE, Romain | |
dc.contributor.author | CABART, Mathilde | |
dc.contributor.author | CAILLET, Philippe | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | BELAROUSSI, Yaniss | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | FRASCA, Matthieu | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | NOIZE, Pernelle | |
dc.contributor.author | WANG, Pascal | |
dc.contributor.author | MEBARKI, Soraya | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | MATHOULIN-PELISSIER, Simone | |
dc.contributor.author | COUDERC, Anne-Laure | |
dc.date.accessioned | 2022-03-16T07:49:42Z | |
dc.date.available | 2022-03-16T07:49:42Z | |
dc.date.issued | 2022-02-02 | |
dc.identifier.issn | 2072-6694 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/136470 | |
dc.description.abstractEn | Systematic molecular profiling and targeted therapy (TKI) have changed the face of Non-Small Cell Lung Cancer (NSCLC) treatment. However, there are no specific recommendations to address the prescription of TKI for older patients. A multidisciplinary task force from the French Society of Geriatric Oncology (SoFOG) and the French Society of Pulmonology/Oncology Group (SPLF/GOLF) conducted a systematic review from May 2010 to May 2021. Protocol registered in Prospero under number CRD42021224103. Three key questions were selected for older patients with NSCLC: (1) to whom TKI can be proposed, (2) for whom monotherapy should be favored, and (3) to whom a combination of TKI can be proposed. Among the 534 references isolated, 52 were included for the guidelines. The expert panel analysis concluded: (1) osimertinib 80 mg/day is recommended as a first-line treatment for older patients with the EGFR mutation; (2) full-dose first generation TKI, such as erlotinib or gefitinib, is feasible; (3) ALK and ROS1 rearrangement studies including older patients were too scarce to conclude on any definitive recommendations; and (4) given the actual data, TKI should be prescribed as monotherapy. Malnutrition, functional decline, and the number of comorbidities should be assessed primarily before TKI initiation. © 2022 by the authors. Licensee MDPI, Basel, Switzerland. | |
dc.language.iso | EN | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.subject.en | Lung cancer | |
dc.subject.en | Targeted therapy | |
dc.subject.en | Efficacy | |
dc.subject.en | Toxicity | |
dc.subject.en | Safety | |
dc.subject.en | Quality of life | |
dc.subject.en | Geriatric assessment | |
dc.title.en | Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/ French-Language Oncology Group (GOLF) | |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.3390/cancers14030769 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 35159036 | en_US |
bordeaux.journal | Cancers | en_US |
bordeaux.volume | 14 | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.issue | 3 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INSERM | en_US |
bordeaux.team | EPICENE_BPH | en_US |
bordeaux.team | AHEAD_BPH | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.export | false | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cancers&rft.date=2022-02-02&rft.volume=14&rft.issue=3&rft.eissn=2072-6694&rft.issn=2072-6694&rft.au=GREILLIER,%20Laurent&GAUVRIT,%20Manon&PAILLAUD,%20Elena&GIRARD,%20Nicolas&MONTEGUT,%20Coline&rft.genre=article |